ArticleAntimicrobial agents and chemotherapy2022
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07013552 (Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Genomic Epidemiology, Antimicrobial Resistance, and Virulence of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characterisation of vancomycin-resistant Enterococcus faecium with Tn1546-plasmid rep17 in obstetrics and gynaecology settings in Algeria.Molecular genetics and genomics : MGG · 2026Article
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- ManagingEClinicalMedicine · 2026Article
- Drug-Resistant Gram-Positive Cocci as Etiological Factors of Cardiac Implantable Electronic Device Infections-Data from the EXTRACT Registry.Antibiotics (Basel, Switzerland) · 2026Article
- Rising burden of enterococcal bacteremia in Victoria, Australia: population-based incidence and antimicrobial resistance trends from three decades of surveillance.Antimicrobial agents and chemotherapy · 2026Article
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
- Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes.BMC infectious diseases · 2025Article
- Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.Antimicrobial agents and chemotherapy · 2025Review
- Genomic Epidemiology of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium ?Clinical orthopaedics and related research · 2025Observational
- Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.Indian journal of microbiology · 2025Article
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- Sentinel Surveillance reveals phylogenetic diversity and detection of linear plasmids harboringAntimicrobial agents and chemotherapy · 2024Article
- Fitness costs of Tn1546-type transposons harboring the vanA operon by plasmid type and structural diversity in Enterococcus faecium.Annals of clinical microbiology and antimicrobials · 2024Article
- The Molecular Mouse System: A New Useful Tool for Guiding Antimicrobial Therapy in Critically Ill Septic Patients.Antibiotics (Basel, Switzerland) · 2024Article
- Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.Infectious diseases and therapy · 2024Article
- Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.Clinical microbiology reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oritavancin displayed potent and stable activity (MIC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.